Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $89.48 million. The enterprise value is $86.35 million.
| Market Cap | 89.48M |
| Enterprise Value | 86.35M |
Important Dates
The last earnings date was Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 11.17 million shares outstanding. The number of shares has increased by 29.65% in one year.
| Shares Outstanding | 11.17M |
| Shares Change (YoY) | +29.65% |
| Shares Change (QoQ) | +7.05% |
| Owned by Insiders (%) | 25.56% |
| Owned by Institutions (%) | 12.02% |
| Float | 8.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.60
| Current Ratio | 1.60 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,166.80%.
| Return on Equity (ROE) | -1,166.80% |
| Return on Assets (ROA) | -372.40% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$7.92M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.85% in the last 52 weeks. The beta is 1.76, so Annovis Bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.76 |
| 52-Week Price Change | -38.85% |
| 50-Day Moving Average | 9.70 |
| 200-Day Moving Average | 10.18 |
| Relative Strength Index (RSI) | 49.71 |
| Average Volume (30 Days) | 533,169 |
Short Selling Information
The latest short interest is 1.61 million, so 14.39% of the outstanding shares have been sold short.
| Short Interest | 1.61M |
| Short Previous Month | 1.50M |
| Short % of Shares Out | 14.39% |
| Short % of Float | 19.74% |
| Short Ratio (days to cover) | 2.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.88M |
| Pretax Income | -47.53M |
| Net Income | -47.53M |
| EBITDA | -47.53M |
| EBIT | -47.53M |
| Earnings Per Share (EPS) | -$5.75 |
Balance Sheet
The company has $3.14 million in cash and no debt, giving a net cash position of $3.14 million or $0.28 per share.
| Cash & Cash Equivalents | 3.14M |
| Total Debt | n/a |
| Net Cash | 3.14M |
| Net Cash Per Share | $0.28 |
| Equity / Book Value | -3.35M |
| Book Value Per Share | -0.30 |
| Working Capital | 2.94M |
Cash Flow
| Operating Cash Flow | -35.37M |
| Capital Expenditures | n/a |
| Free Cash Flow | -35.37M |
| FCF Per Share | -$3.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.65% |
| Shareholder Yield | -29.65% |
| Earnings Yield | -53.12% |
| FCF Yield | -39.53% |
Analyst Forecast
The average price target for Annovis Bio is $19.33, which is 132.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.33 |
| Price Target Difference | 132.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |